179 related articles for article (PubMed ID: 37670301)
1. Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis.
Noori M; Yazdanpanah N; Rezaei N
Cancer Cell Int; 2023 Sep; 23(1):193. PubMed ID: 37670301
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
Wang X; Zhao A; Zhu J; Niu T
Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
[TBL] [Abstract][Full Text] [Related]
3. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review.
Khanam R; Ashruf OS; Waqar SHB; Shah Z; Batool S; Mehreen R; Pachika P; Roksana Z; Rehman MEU; Anwer F
Antibodies (Basel); 2023 May; 12(2):. PubMed ID: 37366654
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.
Tao Y; Zhou H; Niu T
Front Pharmacol; 2021; 12():758992. PubMed ID: 34925019
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
Xiang X; He Q; Ou Y; Wang W; Wu Y
Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
[No Abstract] [Full Text] [Related]
6. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis.
Nejadghaderi SA; Balibegloo M; Noori M; Fayyaz F; Saghazadeh A; Rezaei N
Expert Rev Anticancer Ther; 2023 Mar; 23(3):307-318. PubMed ID: 36856069
[TBL] [Abstract][Full Text] [Related]
9. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
10. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.
Gao X; Zeng H; Zhao X; Wu H; Yan M; Li Y; Zhang G; Sun F
BMC Cancer; 2023 Nov; 23(1):1058. PubMed ID: 37924016
[TBL] [Abstract][Full Text] [Related]
12. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
O'Neill C; van de Donk NWCJ
EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
[TBL] [Abstract][Full Text] [Related]
13. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract][Full Text] [Related]
15. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
Hosny M; Verkleij CPM; van der Schans J; Frerichs KA; Mutis T; Zweegman S; van de Donk NWCJ
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640611
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma.
Zhou X; Einsele H; Danhof S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32659909
[TBL] [Abstract][Full Text] [Related]
17. Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review.
Nejadghaderi SA; Balibegloo M; Saghazadeh A; Rezaei N
PLoS One; 2022; 17(7):e0271506. PubMed ID: 35849585
[TBL] [Abstract][Full Text] [Related]
18. Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China.
Ding K; Yu H; Shao YY; Li LY; Wang CM; Song J; Li LJ; Fu R
Cancer Manag Res; 2020; 12():8935-8941. PubMed ID: 33061589
[TBL] [Abstract][Full Text] [Related]
19. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety.
Swan D; Murphy P; Glavey S; Quinn J
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]